Advertisement

Methods and Process Optimization for Large-Scale CAR T Expansion Using the G-Rex Cell Culture Platform

  • Josh LudwigEmail author
  • Mark Hirschel
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 2086)

Abstract

The G-Rex cell culture platform is based on a gas-permeable membrane technology that provides numerous advantages over other systems. Conventional bioreactor platform technologies developed for large scale mammalian cell expansion are typically constrained by the mechanics of delivering oxygen to an expanding cell population. These systems often utilize complex mechanisms to enhance oxygen delivery, such as stirring, rocking, or perfusion, which adds to expense and increases their overall risk of failure. On the other hand, G-Rex gas-permeable membrane-based bioreactors provide a more physiologic environment and avoid the risk and cost associated with more complex systems. The result is a more robust, interacting cell population established through unlimited oxygen and nutrients that are available on demand. By removing the need to actively deliver oxygen, these bioreactors can hold larger medium volumes (more nutrients) which allows the cells to reach a maximum density without complexity or need for media exchange. This platform approach is scaled to meet the needs of research through commercial production with a direct, linear correlation between small and large devices. In the G-Rex platform, examples of cell expansion (9–14 day duration) include; CAR-T cells, which have atypical harvest density of 20–30 × 106/cm2 (or 2–3 × 109 cells in a 100 cm2 device); NK cells, which have a typical harvest density of 20–30 × 106/cm2 (or 2–3 × 109 cells in a 100 cm2 device) and numerous other cell types that proliferate without the need for intervention or complex processes normally associated with large scale culture. Here we describe the methods and concepts used to optimize expansion of various cell types in the static G-Rex bioreactor platform.

Key words

G-Rex CAR T expansion Process development Large scale T cell culture Suspension culture In vitro cell culture Gas-permeable membrane Bioreactor 

References

  1. 1.
    Wang X, Rivière I (2015) Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies. Cancer Gene Ther 22:85–94.  https://doi.org/10.1038/cgt.2014.81CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Strauss BE, Costanzi-Strauss E (2013) Gene therapy for melanoma: Progress and perspectives. In: Recent advances in the biology, therapy and Management of Melanoma. InTech, London. Chapter 12.  https://doi.org/10.5772/54936CrossRefGoogle Scholar
  3. 3.
    Spyridonidis A, Liga M (2013) Review article: a long road of T-cells to cure cancer: from adoptive immunotherapy with unspecific cellular products to donor lymphocyte infusions and transfer of engineered tumor-specific T-cells. Am J Blood Res 2(2):98–104Google Scholar
  4. 4.
    Spyridonidis A (2012) Cellular immunotherapy for cancer. Past, present, future. Memo Mag Eur Med Oncol 5(2):81–84.  https://doi.org/10.1007/s12254-012-0023-2CrossRefGoogle Scholar
  5. 5.
    Melief CJM, O’Shea JJ, Stroncek DF (2011) Summit on cell therapy for cancer: the importance of the interaction of multiple disciplines to advance clinical therapy. J Transl Med 9(1):107.  https://doi.org/10.1186/1479-5876-9-107CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Brenner MK (2012) Will T-cell therapy for cancer ever be a standard of care? Cancer Gene Ther 19(12):818–821.  https://doi.org/10.1038/cgt.2012.74CrossRefPubMedGoogle Scholar
  7. 7.
    Van Den BC, Keefe R, Schirmaier C, Mccaman M (2014) Therapeutic human cells: manufacture for cell therapy/regenerative medicine. Adv Biochem Eng Biotechnol 138:61–97.  https://doi.org/10.1007/10_2013_233CrossRefGoogle Scholar
  8. 8.
    Bajgain P, Mucharla R, Wilson J et al (2014) Optimizing the production of suspension cells using the G-Rex “M” series. Mol Ther Methods Clin Dev 1:14015.  https://doi.org/10.1038/mtm.2014.15CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Forget M, Haymaker C, Dennison J et al (2016) The beneficial effects of a gas-permeable flask for expansion of tumor-infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity. Oncoimmunology 5:2e1057386CrossRefGoogle Scholar
  10. 10.
    Forget M, Malu S, Liu H et al (2014) Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma. J Immunother 37(9):448–460CrossRefGoogle Scholar
  11. 11.
    Jin J, Sabatino M, Somerville R et al (2012) Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment. J Immunother 35(3):283–292.  https://doi.org/10.1097/CJI.0b013e31824e801fCrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Jin J, Gkitsas N, Fellowes V et al (2018) Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules. J Transl Med 16:13.  https://doi.org/10.1186/s12967-018-1384-zCrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Lapteva N, Durett AG, Sun J et al (2012) Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy 14(9):1131–1143.  https://doi.org/10.3109/14653249.2012.700767CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Lapteva N, Parihar R, Rollins L, Gee A, Rooney C (2016) Large-scale culture and genetic modification of human natural killer cells for cellular therapy. Methods Mol Biol 1441:195–202.  https://doi.org/10.1007/978-1-4939-3684-7_16CrossRefPubMedGoogle Scholar
  15. 15.
    Vera JF, Brenner LJ, Gerdemann U, Ngo MC (2010) Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother 33(3):305–315CrossRefGoogle Scholar
  16. 16.
    Leen AM, Bollard CM, Mendizabal AM et al (2013) Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 121(26):5113–5123.  https://doi.org/10.1182/blood-2013-02-486324CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Wilson Wolf CorporationSt. PaulUSA

Personalised recommendations